Spurred by better understanding of disease biology,improvements in molecular diagnostics,and the development of targeted therapies,the treatment of acute myeloid leukemia(AML)has undergone significant evolution in rec...Spurred by better understanding of disease biology,improvements in molecular diagnostics,and the development of targeted therapies,the treatment of acute myeloid leukemia(AML)has undergone significant evolution in recent years.Arguably,the most exciting shift has come from the success of treatment with the B-cell lymphoma-2 inhibitor venetoclax.When given in combination with a hypomethylating agent or low dose cytarabine,venetoclax demonstrates high response rates,some of which are durable.In spite of this,relapses after venetoclax treatment are common,and much interest exists in elucidating the mechanisms of resistance to the drug.Alterations in leukemic stem cell metabolism have been identified as a possible escape route,and clinical trials focusing on targeting metabolism in AML are ongoing.This review article highlights current research regarding venetoclax treatment and resistance in AML with a focus on cellular metabolism.展开更多
Objective To investigate the frequency of t(14; 18) in different subtypes of B-cell lymphomas and the ability or the polymerase chain reaction(PCR) to detect this rearrangement in frozen samples. Methods 1o7 cases of ...Objective To investigate the frequency of t(14; 18) in different subtypes of B-cell lymphomas and the ability or the polymerase chain reaction(PCR) to detect this rearrangement in frozen samples. Methods 1o7 cases of B-cell lymphomas were studied uslng DNA extracted from rresh-frozen tissues. The DNA samples were amplified by PCR for bcl-2 MBR/JH. The products of bcl-2/JH rearrangement were hybridized with an internal olignucleotide probe or bcl-2 MBR. Results The rearranged bcl-2MBR/JH gene was detected in 13 of the 25(52. o% ) follicular center lymphomas, according to REAL classification: 8 of 11 (72. 7%) grade 1, 2 of 5(40. 0%) grade I, and 3 of 90 (33. 3%) grade, 17 of 82(2o. 8%) cases or difruse large B-cell lymphomas were found to have detectable bel-2 MBR/J. rearrangement- Conclusion The rrequency or bcl-2 MBR/JH rearrangement in diffuse large B-cell lymphomas is significantly lower than those in follicular center lympkomas(X2= 9. 28, P <o. oo5), suggesting that bcl2/JH rearrangements occur mainly in follicular center lymphomas. in addition, the result of reconstruction experiments suggest that amplification or bcl-2 MBR/JH rearrangements by PCR is both sensitive and specific for detection of t (14; 18 ) translocation.展开更多
目的观察昆母汤醇提液(KMT)对人类风湿关节炎成纤维样滑膜细胞(RA-FLS)B淋巴细胞瘤-2基因(bcl-2)、bcl-2相关X蛋白(bax)m RNA及蛋白的影响,探讨昆母汤治疗RA的部分作用机制。方法滑膜组织取自行关节置换术或关节镜检查术的8例活动性类...目的观察昆母汤醇提液(KMT)对人类风湿关节炎成纤维样滑膜细胞(RA-FLS)B淋巴细胞瘤-2基因(bcl-2)、bcl-2相关X蛋白(bax)m RNA及蛋白的影响,探讨昆母汤治疗RA的部分作用机制。方法滑膜组织取自行关节置换术或关节镜检查术的8例活动性类风湿关节炎(RA)患者,分离出FLS并进行原代培养,用逆转录-聚合酶链反应(RT-PCR)观察bax、bcl-2 m RNA表达的变化,采用酶联免疫吸附测定(ELISA)法检测bax、bcl-2蛋白含量的变化。结果与肿瘤坏死因子-α(TNF-α)组比较,KMT高剂量组可以明显促进bax m RNA表达,明显抑制bcl-2 m RNA表达,且bax m RNA/bcl-2 m RNA比值明显提高(P<0.05,P<0.01);KMT中、高剂量组可以提高bax蛋白含量,各剂量组均可降低bcl-2蛋白含量,bax/bcl-2的蛋白比值明显提高(P<0.05,P<0.01),且有一定的剂量依赖性。结论昆母汤可能通过抑制bcl-2的表达,同时促进bax的表达,调节bax/bcl-2比值来发挥对RA-FLS的促凋亡作用,具有治疗RA的潜在价值。展开更多
文摘Spurred by better understanding of disease biology,improvements in molecular diagnostics,and the development of targeted therapies,the treatment of acute myeloid leukemia(AML)has undergone significant evolution in recent years.Arguably,the most exciting shift has come from the success of treatment with the B-cell lymphoma-2 inhibitor venetoclax.When given in combination with a hypomethylating agent or low dose cytarabine,venetoclax demonstrates high response rates,some of which are durable.In spite of this,relapses after venetoclax treatment are common,and much interest exists in elucidating the mechanisms of resistance to the drug.Alterations in leukemic stem cell metabolism have been identified as a possible escape route,and clinical trials focusing on targeting metabolism in AML are ongoing.This review article highlights current research regarding venetoclax treatment and resistance in AML with a focus on cellular metabolism.
文摘Objective To investigate the frequency of t(14; 18) in different subtypes of B-cell lymphomas and the ability or the polymerase chain reaction(PCR) to detect this rearrangement in frozen samples. Methods 1o7 cases of B-cell lymphomas were studied uslng DNA extracted from rresh-frozen tissues. The DNA samples were amplified by PCR for bcl-2 MBR/JH. The products of bcl-2/JH rearrangement were hybridized with an internal olignucleotide probe or bcl-2 MBR. Results The rearranged bcl-2MBR/JH gene was detected in 13 of the 25(52. o% ) follicular center lymphomas, according to REAL classification: 8 of 11 (72. 7%) grade 1, 2 of 5(40. 0%) grade I, and 3 of 90 (33. 3%) grade, 17 of 82(2o. 8%) cases or difruse large B-cell lymphomas were found to have detectable bel-2 MBR/J. rearrangement- Conclusion The rrequency or bcl-2 MBR/JH rearrangement in diffuse large B-cell lymphomas is significantly lower than those in follicular center lympkomas(X2= 9. 28, P <o. oo5), suggesting that bcl2/JH rearrangements occur mainly in follicular center lymphomas. in addition, the result of reconstruction experiments suggest that amplification or bcl-2 MBR/JH rearrangements by PCR is both sensitive and specific for detection of t (14; 18 ) translocation.
文摘目的观察昆母汤醇提液(KMT)对人类风湿关节炎成纤维样滑膜细胞(RA-FLS)B淋巴细胞瘤-2基因(bcl-2)、bcl-2相关X蛋白(bax)m RNA及蛋白的影响,探讨昆母汤治疗RA的部分作用机制。方法滑膜组织取自行关节置换术或关节镜检查术的8例活动性类风湿关节炎(RA)患者,分离出FLS并进行原代培养,用逆转录-聚合酶链反应(RT-PCR)观察bax、bcl-2 m RNA表达的变化,采用酶联免疫吸附测定(ELISA)法检测bax、bcl-2蛋白含量的变化。结果与肿瘤坏死因子-α(TNF-α)组比较,KMT高剂量组可以明显促进bax m RNA表达,明显抑制bcl-2 m RNA表达,且bax m RNA/bcl-2 m RNA比值明显提高(P<0.05,P<0.01);KMT中、高剂量组可以提高bax蛋白含量,各剂量组均可降低bcl-2蛋白含量,bax/bcl-2的蛋白比值明显提高(P<0.05,P<0.01),且有一定的剂量依赖性。结论昆母汤可能通过抑制bcl-2的表达,同时促进bax的表达,调节bax/bcl-2比值来发挥对RA-FLS的促凋亡作用,具有治疗RA的潜在价值。
